SIMPLIFY Study for Cystic Fibrosis


Trial Objective

SIMPLIFY Study for Cystic FibrosisDespite the increasingly common use of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator therapies in treating CF, it is still largely unknown whether or not other chronic therapies can be safely stopped. In the SIMPLIFY study, researchers are trying to determine whether or not it is safe for people to stop taking either inhaled hypertonic saline or Pulmozyme® (dornase alfa) if they are also taking Trikafta™. 


Active Clinical Trials Currently Recruiting

Who Can Participate

Individuals 12 year of age and up with CF who have been taking Trikafta™ for at least 90 days and also use hypertonic saline, and/or Pulmozyme® (dornase alfa).

Age: 12+    Gender: Any Gender

Estimated Time Commitment

4 study visits, 1 phone call and daily questionnaires over 8 weeks

Brief monthly questionnaires for about 6 months after the final study visit.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Renee Plomondon

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Cystic Fibrosis Foundation (CFF), managed by the Therapeutic Development Network Coordinating Center (TDNCC)


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: